Is the use of Ondensetron safe in patients on hemodialysis? Checkout the VA by NSMC intern Santhoshi Bavi
CYCLE HD: The Visual Abstract
Superb work by Mythri Shankar for this week’s NephJC on exercise in hemodialysis
This week, we will discuss the first iteration of KDIGO’s 2025 guidelines on ADPKD. These guidelines are a result of a decade of global collaboration between physicians, researchers, advocates, and patients. The guidelines incorporate ADPKD-specific care as well as many general CKD management practice points.
This week, we will celebrate in advance World Kidney Day by discussing the results of OBInutuzumab in active lupus nephritis. The LUNAR trial (rituximab versus placebo) was “almost” positive, but not quite there. Would Obi overpower its cousin ritux? ✨
This week, we will continue with February’s aldosterone leitmotif: do mineralocorticoid receptor antagonists (MRAs) truly blind the diagnostic in unilateral hypraldosteronism? Is this the article the mythbuster? Draw your own conclusions
This week, we will discuss the origins of primary hyperaldosteronism in normotensive patients. Could this undetected anomaly be the cause of idiopathic hypertension and CKD?
Is the use of Ondensetron safe in patients on hemodialysis? Checkout the VA by NSMC intern Santhoshi Bavi
Superb work by Mythri Shankar for this week’s NephJC on exercise in hemodialysis